Capital International Investors’s NewAmsterdam Pharma NAMS Stock Holding History

Capital International Investors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.1M	Sell	1,441,131 -621,404	-30%	-$20.2M	0.01%	340
2025 Q4	$72.4M	Hold	2,062,535	–	–	0.01%	323
2025 Q3	$58.7M	Hold	2,062,535	–	–	0.01%	332
2025 Q2	$37.4M	Hold	2,062,535	–	–	0.01%	353
2025 Q1	$42.2M	Hold	2,062,535	–	–	0.01%	334
2024 Q4	$53M	Buy	+2,062,535	New	+$43.8M	0.01%	336

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Capital International Investors's NAMS Position: Q1 2026 in Review

Capital International Investors reduced its NewAmsterdam Pharma (NAMS) stake by 30% in Q1 2026, selling an estimated $20.2M and leaving 1,441,131 shares worth $46.1M. The position accounts for 0.01% of the portfolio, ranked #340.

Capital International Investors first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. The position peaked at $72.4M in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Capital International Investors held 1,441,131 shares of NewAmsterdam Pharma worth $46.1M as of Q1 2026.
Capital International Investors sold 621,404 NewAmsterdam Pharma shares in Q1 2026, an estimated $20.2M.
NewAmsterdam Pharma made up 0.01% of Capital International Investors's portfolio in Q1 2026, its #340 holding.
Capital International Investors first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
Capital International Investors's NewAmsterdam Pharma position peaked at $72.4M in Q4 2025.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Capital International Investors's 13F filing for Q1 2026, filed 13 May 2026.